Pharma Company Bags Rs 127.20 Crore Order from Central Medical Services Society (CMSS)

Panacea Biotec Limited has received a domestic order from the Central Medical Services Society (CMSS), under the Ministry of Health and Family Welfare, Government of India, for the supply of the bivalent oral polio vaccine (bOPV). The total value of this contract is approximately Rs 127.20 Crore. The vaccine will be supplied in several tranches over a period ranging from 90 to 480 days from the Letter of Acceptance date, which was October 8, 2025.

Earlier, the company secured a significant Long-Term Agreement (LTA) with UNICEF to supply the bivalent oral polio vaccine (bOPV), valued at approximately USD 35.65 million (around Rs 315 crore) for the delivery period covering the second quarter of Calendar Year 2026 and all of Calendar Year 2027. The overarching LTA runs from April 1, 2026 to March 31, 2030 and the agreement focuses on the international supply of bOPV in 10 and 20-vial presentations, with key details to be published on UNICEF's website as part of their transparency policy.

About the Company

Established in 1984, Panacea Biotec Ltd stands as a research-driven biotechnology company deeply involved in the research, development, manufacturing, and marketing of a diverse portfolio encompassing branded vaccines, pharmaceutical formulations, nutraceuticals, and food & nutrition products. Notably, Panacea Biotec has emerged as one of India's leading vaccine manufacturers and has garnered recognition from the United Nations (UN) Health Agencies for its significant contributions to the Global Polio Eradication Initiative (GPEI), having supplied billions of doses of WHO-prequalified polio vaccines to over 50 countries following its comprehensive range of oral polio vaccines.

The company has a market cap of over Rs 2,600 crore and the stock is up by 66 per cent from its 52-week low of Rs 268.10 per share.

Disclaimer: The article is for informational purposes only and not investment advice.